Hence, the increased expression of Kv1.3 has been observed in AD, ischemic stroke, and Parkinson’s disease, and with the pharmacological or genetic inhibition of Kv1.3, both pathological and neurological outcomes have improved in relevant animal models [208,212,213]. The gene discussed is KCNA3; the disease is Alzheimer disease.